Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Onyx Biotec IPO
Price Band
₹58.0–61.0
Issue Size
₹29.34 Cr
Lot Size
2,000 shares
Min Investment
₹122,000
GMP
+₹5.0 (8.2%)
Issue Price
₹61.0
Subject to Sauda
₹7600
Paid only if allotted
Onyx Biotec IPO AI Summary
- Onyx Biotec IPO is listed on NSE SME in the Pharmaceuticals sector.
- Price band: ₹58.0–₹61.0 per share, lot size 2,000 shares (min. investment ₹122,000).
- Subscription window: 13 Nov–18 Nov 2024, listing on 22 Nov 2024.
- Current GMP is +₹5.0 (8.2%), an estimated listing price of ₹66 — unofficial and can change daily.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Onyx Biotec IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 18 Nov 2024 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Onyx Biotec IPO Grey Market Premium (GMP) Today
GMP
+₹5.0
GMP %
+8.2%
Est. Listing
₹66.0
Updated: 25 Jul 2026 14:03
About the Company
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets. The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift. The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others. As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies. The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited. As of July 31, 2024, the company has 175 employees across various departments.
Company Financials (₹ Cr)
As of 2024-05-31
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 74.77 | 74.14 | 58.72 | 36.84 |
| Total Income | 10.54 | 53.87 | 39.62 | 44.98 |
| Profit After Tax | 1.31 | 3.03 | 1.84 | 3.35 |
| NET Worth | 26.19 | 24.88 | 18.20 | 16.38 |
| Reserves and Surplus | 12.86 | 11.56 | 12.30 | 10.47 |
| Total Borrowing | 31.56 | 30.78 | 29.23 | 12.24 |
Key Ratios
EPS
₹2.28
NAV
₹19.66
ROE
4.99%
ROCE
3.71%
RoNW
4.99%
P/B Value
3.10
P/E Ratio
26.81
Market Cap
₹110.61 Cr
PAT Margin
12.42%
Debt/Equity
1.21
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| JB Chemicals | 188.37 | 18.9% | 53.63 | 35.66 | 35.66 |
| Suven Pharmaceuticals Limited | 375.82 | 14.64% | 83.92 | 11.8 | 11.8 |
| Onyx Biotec Limited This IPO | 18.67 | 12.19% | 26.81 | 2.28 | 2.28 |
Promoters
Sanjay Jain, Naresh Kumar and Fateh Pal Singh
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use; 6.08 2 Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections; 1.24 3 Prepayment or repayment of all or a portion of certain loans availed by the Company; and 12.00 4 General Corporate Purposes 6.00
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹44.98 Cr for the period ending 31 Mar 2022, then decreased to ₹39.62 Cr by 31 Mar 2023. It increased to ₹53.87 Cr by 31 Mar 2024, but fell significantly to ₹10.54 Cr by 31 May 2024, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹3.35 Cr for the period ending 31 Mar 2022, which decreased to ₹1.84 Cr by 31 Mar 2023. It then rose to ₹3.03 Cr by 31 Mar 2024, but dropped to ₹1.31 Cr by 31 May 2024, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
Onyx Biotec Limited's implied P/E at the issue price of ₹61.0 is approximately 26.81, compared to peer group P/E ratios ranging from 53.63 to 83.92.
Grey Market Premium, Explained
The Grey Market Premium (GMP) refers to the unofficial trading of IPO shares before they are listed on the stock exchange. A positive GMP indicates that the shares are expected to list at a higher price than the issue price, while a negative GMP suggests the opposite. Investors often look at GMP to gauge market sentiment towards an IPO.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and risk tolerance. It is essential to consider the company's financial health, market conditions, and individual investment goals.
Who May Want to Wait
Investors who prefer stable returns and are risk-averse may want to avoid this IPO, especially given the recent fluctuations in the company's revenue and profit figures. Those who are not prepared for the potential volatility associated with IPO investments should also consider other options.
IPO Timeline, Explained
The IPO is set to open on November 13, 2024, and will close on November 18, 2024. Allotment of shares is expected to occur on November 19, 2024, with the listing date scheduled for November 22, 2024.
Listing Gains — The Risk
Listing-day gains can be unpredictable. While some IPOs may see a surge in stock price on their first day of trading, others may not perform as well. Factors influencing listing performance include market conditions, investor sentiment, and the company's financial health. Investors should be cautious and not solely rely on potential listing gains.
This evaluation is generated from Onyx Biotec's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Onyx Biotec IPO GMP today?
Onyx Biotec IPO GMP today is +₹5.0 (8.2%), indicating an estimated listing price of ₹66. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Onyx Biotec IPO?
The price band of Onyx Biotec IPO is ₹58.0–₹61.0 per share.
When does Onyx Biotec IPO open and close?
Onyx Biotec IPO opens on 13 November 2024 and closes on 18 November 2024.
When does Onyx Biotec IPO list on the stock exchange?
Onyx Biotec IPO listed on 22 November 2024 at ₹66.0.
What is the lot size for Onyx Biotec IPO?
The lot size for Onyx Biotec IPO is 2000 shares, requiring a minimum investment of ₹122,000.
What is the price band for the Onyx Biotec IPO?
The price band for the Onyx Biotec IPO is ₹58.0 to ₹61.0.
What is the minimum investment required?
The minimum investment required is ₹122,000, which corresponds to a lot size of 2000 shares.
When is the listing date for the shares?
The listing date for the shares is November 22, 2024.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium or discount at which an IPO is likely to list compared to its issue price.
What is the allotment date for the IPO?
The allotment date for the IPO is November 19, 2024.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
13 Nov 2024
Close
18 Nov 2024
Allotment
19 Nov 2024
Listing
22 Nov 2024
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Onyx Biotec?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.